Pharmacogenomic Applications
Dynemo can be used by pharmaceutical companies as a means of focusing selection of clinical trial subjects to those most likely to respond to a therapeutic, thus enhancing the likelihood of success of a trial. Using gene expression data garnered from clinically annotated patient samples in earlier studies, Dynemo will define modularity signatures that can be used as biomarkers to predict response in subsequent trials.
The same methodology can be applied to revive failed drugs in cases where efficacy was too low to justify further expense but a number of patients did respond to the drug.
In either case, upon discovery of a modularity signature, a companion diagnostic will be advantageous in detecting the signature in the next phase of the trial and when the drug becomes available on the market. A proprietary companion diagnostic has the potential to extend non-generic exclusivity. Additionally, the FDA is pressuring trial sponsors to include pharmacogenomic information in clinical study reports. Dynemo offers full service diagnostic assay development for detecting modularity signatures through its partnership with Mount Sinai Services, an independent CLIA laboratory.
Mechanism of Action
Dynemo can analyze microarray data taken before and after therapeutic intervention to determine what effects the drug or drug combination has on the organization of the protein interaction network in a cell or animal model. Combined with an understanding of what network organization pattern results in drug-response, this information can assist in understanding the drug’s mechanism of action.
Dynemo can be used by pharmaceutical companies as a means of focusing selection of clinical trial subjects to those most likely to respond to a therapeutic, thus enhancing the likelihood of success of a trial. Using gene expression data garnered from clinically annotated patient samples in earlier studies, Dynemo will define modularity signatures that can be used as biomarkers to predict response in subsequent trials.
The same methodology can be applied to revive failed drugs in cases where efficacy was too low to justify further expense but a number of patients did respond to the drug.
In either case, upon discovery of a modularity signature, a companion diagnostic will be advantageous in detecting the signature in the next phase of the trial and when the drug becomes available on the market. A proprietary companion diagnostic has the potential to extend non-generic exclusivity. Additionally, the FDA is pressuring trial sponsors to include pharmacogenomic information in clinical study reports. Dynemo offers full service diagnostic assay development for detecting modularity signatures through its partnership with Mount Sinai Services, an independent CLIA laboratory.
Mechanism of Action
Dynemo can analyze microarray data taken before and after therapeutic intervention to determine what effects the drug or drug combination has on the organization of the protein interaction network in a cell or animal model. Combined with an understanding of what network organization pattern results in drug-response, this information can assist in understanding the drug’s mechanism of action.
